<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976557</url>
  </required_header>
  <id_info>
    <org_study_id>PL-13732</org_study_id>
    <nct_id>NCT03976557</nct_id>
  </id_info>
  <brief_title>BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden</brief_title>
  <acronym>IMPROWE</acronym>
  <official_title>Implementation and Evaluation of BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden. Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bactiguard AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bactiguard AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is to establish the incidence of all any catheter related
      complications in BIP CVC and standard CVC groups in patients requiring CVC.

      (CVC - Central Venous Catheter; BIP - Bactiguard Infection Protection)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter related complications include CRBSI, CRI, Local CVC infection, need to exchange of
      CVC due to suspected CRI/CRBSI or thrombosis, stop / slower flow in any CVC lumen, local
      thrombosis, device malfunctions / technical catheter problems, device related adverse events.

      (CRBSI - Catheter Related Blood Stream Infection; CRI - Catheter Related Infection)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilot, randomized, open label, controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with catheter related complications</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Patients having any complication specified as secondary endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CRBSI</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>CRBSI - Catheter Related Blood Stream Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CRI</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>CRI - Catheter Related Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with local CVC infections</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Skin infection at the insertion site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CVC exchanges per patient due to suspected infection or thrombosis</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Reported as incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with stop or slower flow in any CVC lumen</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Stop or slower flow or need of high pressure during blood sample withdrawal and/or injection of solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with local thrombosis</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Local thrombosis - thrombosis in the insertion vein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with device malfunctions</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>Any device malfunction or technical problems during insertion, withdrawal or use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with antibiotics and antithrombotics drug use</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>including the reason of use and dose / number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From CVC insertion until CVC withdrawal</time_frame>
    <description>including casuality assessment to the CVC use; both serious and non-serious</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vascular Access Complication</condition>
  <condition>Catheter-Related Infections</condition>
  <condition>Catheter Thrombosis</condition>
  <condition>Catheter Blockage</condition>
  <condition>Catheter Complications</condition>
  <condition>Catheter Site Discomfort</condition>
  <condition>Catheter Bacteraemia</condition>
  <arm_group>
    <arm_group_label>BIP CVC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polyurethane CVC with noble metal coating</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard CVC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard CVC made of polyurethane</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIP CVC</intervention_name>
    <description>Central venous access with noble metal coated CVC</description>
    <arm_group_label>BIP CVC</arm_group_label>
    <other_name>Noble metal coated CVC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard CVC</intervention_name>
    <description>Central venous access with standard uncoated CVC</description>
    <arm_group_label>Standard CVC</arm_group_label>
    <other_name>Uncoated CVC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to the Access Center at Danderyd who need an elective CVC (surgery,
             infection, nutrition, medicationâ€¦)

          2. Fully recognize and understand patient information

          3. Signed informed consent

        Exclusion Criteria:

          1. If CVC present prior to inclusion in the study and no intention to change the present
             CVC over guidewire

          2. Age &lt; 18 years

          3. Pregnant women

          4. Known allergy to gold, silver and palladium

          5. Participation in other clinical studies which may interfere with this study as judged
             by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Jakobsson, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danderyd Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorota Johansson, PhD</last_name>
    <phone>46 70 6543171</phone>
    <email>dorota.johansson@bactiguard.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ylva Kai-Larsen, PhD</last_name>
    <phone>46 73 511 04 11</phone>
    <email>ylva.kai-larsen@bactiguard.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyd Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

